ArticleMolecular cancer therapeutics2016
Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Article in Molecular cancer therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.Investigational new drugs · 2023Pooled it
- Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy.RSC medicinal chemistry · 2025Article
- Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein.Journal of medicinal chemistry · 2025Article
- Review
- Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.NPJ precision oncology · 2024Article
- Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.Nature cancer · 2023Article
- Review
- Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.Molecular cancer therapeutics · 2023Article
- Progress and challenges in RET-targeted cancer therapy.Frontiers of medicine · 2023Review
- RET kinase inhibitors forTherapeutic advances in medical oncology · 2022Review
- RET receptor signaling: Function in development, metabolic disease, and cancer.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2022Review
- Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.MedComm · 2021Review
- Precision therapy for RET-altered cancers with RET inhibitors.Trends in cancer · 2021Review
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.Journal of medicinal chemistry · 2021Review
- [Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.Scientific reports · 2021Article
- Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.Current treatment options in oncology · 2021Review
- The importance of the RET gene in thyroid cancer and therapeutic implications.Nature reviews. Endocrinology · 2021Review
- Review
- Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.Annals of oncology : official journal of the European Society for Medical Oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
RET fusions have been found in lung adenocarcinoma, of which KIF5B-RET is the most prevalent. We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. Doxycycline-induced CCSP-rtTA/tetO-KIF5B-RET transgenic mice developed invasive lung adenocarcinoma with desmoplastic reaction. Tumors regressed upon suppression of KIF5B-RET expression. By culturing KIF5B-RET-dependent BaF3 (B/KR) cells with increasing concentrations of cabozantinib or vandetanib, we identified cabozantinib-resistant RET
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.